The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare syste...

Full description

Bibliographic Details
Main Authors: Doreen A. Ezeife, Eldon Spackman, Rosalyn A. Juergens, Janessa J. Laskin, Jason S. Agulnik, Desiree Hao, Scott A. Laurie, Jennifer H. Law, Lisa W. Le, Lesli A. Kiedrowski, Barbara Melosky, Frances A. Shepherd, Victor Cohen, Paul Wheatley-Price, Rachel Vandermeer, Janice J. Li, Roxanne Fernandes, Aria Shokoohi, Richard B. Lanman, Natasha B. Leighl
Format: Article
Language:English
Published: SAGE Publishing 2022-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221112696

Internet

https://doi.org/10.1177/17588359221112696

Similar Items